ANI Pharmaceuticals reported a 27.6% increase in Q3 2026 net revenues to $290.8 million, driven by strong growth in its Rare Disease segment, especially Cortrophin Gel, which grew 36.1%. The company also announced an offer to acquire Egetis Therapeutics, expanding its Rare Disease portfolio with EMCITATE®, a rare genetic disorder treatment. ANI narrowed its 2026 revenue guidance and raised earnings forecasts, focusing on growth and integration of the acquisition. The company repurchased $20 million in stock year-to-date and plans to expand its specialty pharmacy network to meet demand.
ANI Pharmaceuticals' Q3 2026 financial results provide context for readers, with Pluang market data as of Nov 05, 2026 18:11 WIB. Among 150 priced Health-sector US stocks tradable on Pluang, 85 rose and 56 fell today. Notable movers include FLNA at USD 0.63 with a 9.21% increase, ADPT at USD 28.28 with a 5.88% rise and 100% buy order activity, and ACHC at USD 34.05 with a 5.58% gain but 89% sell order activity.
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
